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ABSTRACT

Elucidating Metabolic and Drug Resistance Adaptations of Morganella morganii with
Possible Links to Virulence (August 2019)
Yuridia Rodriguez, B.S., Texas A&M International University
Chair of Committee: Dr. Daniel J. Mott
The human gut microbiome has recently gained more attention due to its possible links to
metabolic disorders such as obesity, autoimmune disorders, gastrointestinal disorders, and
stress-related disorders such as depression and anxiety. In addition, the gut microbiome is
often a cause of nosocomial infections due to the fact that they can be opportunistic
pathogens. Therefore, many studies are now focusing on the bacteria that belong to the
human gut microbiota. One such bacterium is named Morganella morganii. M. morganii is a
gram-negative rod shaped bacterium that belongs to the Enterobacteriaceae family. It is a
highly adaptive species of bacteria that has clinically been shown to cause infections ranging
from septic arthritis to brain abscesses to the most common type being urinary tract
infections. However, most studies focus on the clinical aspect of this organism. Therefore,
although we have a broad picture at the types of infections that this organism causes, we do
not know how it is able to become pathogenic. In order to begin understanding M. morganii’s
pathogenicity, it is vital that we begin to study this organism at the molecular level.
Therefore, this study will focus on creating a basic metabolic and drug resistance profile for
an organism that is relatively unknown at the molecular level.
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INTRODUCTION
History of Microbes
The discovery of microorganisms led by Robert Hooke and Antoni Van
Leeuwenhoek in the mid 1600’s, paved the way for the world of microbiology.
Consequently, once it was discovered that these tiny organisms existed, the germ theory of
disease established by Louis Pasteur and Robert Koch, showed that these microscopic
organisms were capable of causing disease. After this hypothesis was accepted,
microorganisms gained a reputation of being solely pathogenic, therefore, an emphasis was
placed on eradicating them. The accidental discovery of the antimicrobial agent now known
as penicillin by Alexander Fleming in 1923 paved the way for the world of antibiotics that
would accomplish this. Since microorganisms, especially bacteria, were now viewed in a
negative light, there was a general understanding that bacteria were our enemies. This is still
a popular mentality, but within the scientific community this way of thinking has shifted so
that most bacteria are now thought of as being commensal organisms. One of the first people
to discover this was Martinus Beijernick. His work primarily focused on the ability of
bacteria to fixate atmospheric nitrogen into ammonia which is a usable form by plants. In
addition, Arthur I. Kendall was one of the first to publish a paper outlining the commensal
relationship between bacteria in the human intestinal tract and their host [1]. Although their
work was initially met with resistance by the scientific community due to the prevalent
mindset that bacteria were only disease causing organisms, eventually several scientists like
This thesis follows the model of PLOS Biology.
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Theodor Escherich, Elie Metchnikoff, and Theodor Rosebury decided to study the
partnership between bacteria and their human hosts [2–4]. This led to what is now the widely
studied field of human microbiome research.
Microbiota Overview
Microbiome research is still in its infancy, but it is currently experiencing an
increasing amount of public interest due to the many potential benefits that the bacteria that
live within us have to offer. This is evident by the increasing number of probiotics that are
readily available on the market. Every organism, with the exception of germ-free organisms
created in the laboratory setting, are inhabited by microorganisms. In humans,
microorganisms outnumber human cells by a narrow margin. In addition, once you compare
the number of microbes that inhabit our bodies with the number of stars in the Milky Way,
you find that there are 100 trillion microbes whereas the Milky Way contains only around
100 to 400 million stars [5]. Out of these 100 trillion microbes, most of them are found to
inhabit the human intestinal tract or gut. Therefore, many research projects are focusing on
the human gut microbiome and are finding connections between specific species of bacteria
and the role they play in disease.
Inside the human gut
The human gut is a highly dynamic and heterogeneous environment due to the
presence of both dietary and endogenous metabolites [6]. These metabolites are taken up by
bacteria that normally inhabit the gut and shape the composition of the human gut microbiota
[7]. Therefore, the metabolites present in the human gut offer an indication of which bacterial
species make up the gut microbiota. With microbiota research still in its infancy, it becomes
important to create a metabolic profile for species of bacteria that have been found to
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normally inhabit the gastrointestinal (GI) tract because this will provide insight into how they
are able to adapt to such a dynamic environment. The GI tract is covered in a mucosal layer.
Mucus both protects the underlying epithelial cells from invasion of pathogenic bacteria, and
it can also provide the necessary nutrients for commensal bacteria to thrive [8]. Mucus is
made up of mucin proteins which are themselves heavily glycosylated [8]. The proteins that
are attached to the mucin proteins are very diverse; therefore, they offer a number of
metabolites for uptake by bacterial species found in the human gut [8]. This mucosal layer is
divided into two parts: the underlying inner layer or adherent layer and the outer layer or
non-adherent layer [8].

Figure 1. Close up look at epithelial lining in human gut. The inner layer is comprised of
glycoproteins that are tightly packed while the outer layer contains loosely bound
glycoproteins and it houses both pathogenic and commensal bacteria.
The inner layer is free of any bacteria while the outer layer houses most of the bacteria
belonging to the human gut microbiota [9]. Therefore, most bacterial interactions will occur
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in the outer layer of the mucosal layer, and this is where most commensal species of bacteria
are found.
Human gut microbiota overview
The gut microbiota are the many microorganisms that are found in the human
intestinal lining. In the gut, these bacteria are mostly found in the outermost mucosal layer.
Mucus is able to harbor commensal bacteria by providing them a place to adhere, as well as
providing them the necessary environment for them to thrive [8]. Since many different
species of bacteria reside in the outermost mucosal layer, there are many interactions that
occur between both commensal and pathogenic bacteria that are trying to breach the
epithelial layer. The use of antibiotics has been widely known to decrease the diversity of the
human microbiota because they do not discriminate between pathogenic and commensal
bacteria. Therefore, this results in less competition between the two which allows pathogenic
bacteria to colonize and invade the GI tract [10]. In a world driven by antibiotic overuse, it
has become increasingly important to maintain a diverse human microbiota. Increasing
diversity can be accomplished by using probiotics. There are three possible mechanisms of
action for their contribution to human health: allowing the live bacteria provided in the
probiotics to outcompete pathogenic bacteria either directly or indirectly, enhancing
epithelial structure so that it produces more mucus to protect against foreign pathogens, and
dominating areas of the GI tract that have relatively few commensal bacteria but have an
enormous impact on the functioning of the immune system [11]. The commensal bacteria can
either promote the competitive exclusive of pathogenic bacteria or promote their expansion
in the gut lining [10]. For instance, it was found that the Lactobacillus casei strain DN114001 was shown to prevent the binding of adherent-invasive Escherichia coli (AIEC) to
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intestinal epithelial cells thereby diminishing the symptoms caused by Crohn’s disease [12].
In addition, it was found that mice pretreated with Lactobacillus helveticus strain R0052 and
Lactobacillus rhamnosus strain R0011, led to a reduction of colonization of the bacterium
Citrobacter rodentium which resulted in the amelioration of the symptoms of Crohn’s
disease [13]. However, it has also been shown that bacteria belonging to the human gut
microbiota can allow pathogenic bacteria to proliferate the epithelial lining. For instance, the
normally saprophylic bacterium Bacteroides thetaiotaomicron is a prominent member of the
gut microbiota. However, B. thetaiotaomicron contains enzymes that are able to produce
succinate which can then be converted by the very well-known pathogen Clostridium difficile
into butyrate which it uses to proliferate [14]. In addition, it has the ability to break apart
mucin into fucose via various fucosidases [15]. This newly released fucose can then be taken
up by enterohaemorrhagic E. coli (EHEC) where it plays a regulatory role in its
pathogenicity and metabolism [15].
In addition, the human gut microbiota has recently gained more attention due to its
possible links to metabolic disorders such as obesity, type 2 diabetes, autoimmune disorders,
gastrointestinal disorders such as Crohn’s disease, and stress-related disorders such as
depression and anxiety [16–19]. These disorders have been found to be triggered by an
imbalance between protective and harmful species of bacteria, a process termed dysbiosis
[20]. Obesity is often characterized by having a high Firmicutes/Bacteroidetes ratio [21].
Therefore, a reduction in bacteria belonging to the phylum Bacteroidetes with a concurrent
increase in bacterial species belonging to the phylum Firmicutes is often thought of as being
one factor that leads to the increase of obesogenic properties. However, when it comes to
characterizing Crohn’s disease, there is often a decrease in species of bacteria belonging to
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the phlyum Firmicutes in patients with this disease [18]. Therefore, a better way to
characterize dysbiosis would be to focus on the functionality of bacteria. Instead of trying to
establish a core microbiota, emphasis should be placed on establishing core functions. For
instance, it was found that there was a dysbiosis between healthy patients and those who
presented Crohn’s disease but instead of there being an imbalance between different species
of bacteria, there was an imbalance in the ability of bacteria to produce butyrate and degrade
mucin [22]. These functions could lead to expression of specific virulence factors.
Therefore, discovering which metabolites are selectively uptaken by specific species of
bacteria can provide insight into how these bacteria are able to function and become virulent.
The role of carbon metabolism in virulence
Carbon sources are known to give bacteria a growth advantage. Recent studies have
found that these carbon sources can also trigger the expression of specific virulence factors.
In some species of bacteria, it has been shown that the Phosphotransferase Transport System
(PTS) is able to modulate the expression of virulence factors when they come in contact with
specific carbon sources. In Salmonella enterica a PTS known as EIIAGlc activated the type
three secretion system 2 (TTSS-2) when it came in contact with the sugars glucose or Nacetyl-muramic acid. The TTSS-2 in turn activated virulence factor secretion [23]. It was
also shown that EHEC are able to regulate expression of the locus of enterocyte effacement
(LEE) which codes for a type III secretion system (T3SS), when it sensed fucose in its
environment via a two-component system (TCS) [15]. These T3SSs have been found in both
commensal and pathogenic species of Gram-negative bacteria, but in pathogenic bacteria
they have been found to invade other cells by injecting effectors directly into the host cell’s
cytoplasm [24]. Since this virulence factor is found in both commensal and pathogenic
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species of bacteria, it can provide insight into the ability of bacteria to alternate from a
saprophytic to a pathogenic lifestyle in the highly dynamic environment of the human GI
tract. Another virulence factor is the ethanolamine utilization (eut) operon. Ethanolamine is a
source of carbon and nitrogen that is not often used by commensal species of bacteria [25].
Instead, ethanolamine is selectively used by several pathogenic species of bacteria such as
EHEC which provides them with a growth advantage [26]. This allows pathogenic species of
bacteria to survive in the GI tract and outcompete several commensal species of bacteria,
thereby increasing their chances of penetrating the epithelial layer. Ethanolamine is derived
from phosphatidylethanolamine, a lipid that is often found in eukaryotic and bacterial cell
membranes. When enterocytes are exfoliated or when there is turnover of bacterial cells,
ethanolamine becomes abundant in the GI tract [25]. One Gram-negative species bacterium,
Morganella morganii, is considered to be a commensal species, and is known to contain the
eut operon [27]. This may allow M. morganii to have a competitive advantage over other
commensal species of bacteria. In addition, to containing the eut operon, M. morganii is also
known to contain a urease gene cluster ureABCEFGD [28]. However, in other species of
bacteria such as P. mirabilis HI4320 and Providen ciarettgeri DSM1131 where this urease
gene cluster has also been found, the urease regulatory gene ureR is also present [29].
Morganella morganii has been found to lack this regulatory gene but instead it contains a
urea transporter [27]. In light of these findings, it becomes vital to study the metabolites that
members of the human gut microbiota such as M. morganii interact with in order to
understand any further implications that these species have on surrounding bacteria, whether
they be commensal or pathogenic. Creating a metabolic profile for M. morganii will allow us
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to test which carbon sources affect its growth and protein expression, and it will allow us to
better understand the connection between carbon metabolism and virulence.
M. morganii characteristics
Morganella morganii is a Gram-negative, rod shaped bacterium that belongs to the
phylum Proteobacteria. Although, originally classified as a member of the genus Proteus, M.
morganii gained its own place as the only species in the genus Morganella, including the two
subspecies morganii and sibonii [27]. It gained this status through DNA-DNA hybridization
results that showed that it was less than 20% related to other members of the genus Proteus
[30]. Its genome size is approximately 4 Mbp and it harbors around 3,600 protein coding
genes [27]. In addition, M. morganii has a fully sequenced genome, yet 22% of it has no
known protein function [27]. Morganella morganii is a highly adaptive species of bacterium
that has been found in environments ranging from the soil to the human gut [28]. Past studies
have classified M. morganii as an opportunistic pathogen that is mostly associated with
postoperative and nosocomial infections especially of the urinary tract [27]. Further studies
revealed that it can also cause an array of infections such as septic arthritis,
meningoencephalitis, sepsis, bacteremia, and brain abscesses [31–35]. Morganella morganii
is classified as being an uncommon pathogen due to its low infection rate. However, it is not
often detected in clinical tests; therefore, infections caused by this bacterium are
underestimated [36]. Morganella morganii also has the ability to form partnerships with
other species of bacteria such as Pseudomonas aeruginosa that is also becoming increasingly
antibiotic resistant and also belongs to the human gut microbiota, thereby enhancing the
threat of this organism. Therefore, special attention should be paid to organisms like this that
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have already shown the ability to become antibiotic resistant and have the potential to still
acquire even more resistance.
M. morganii partnerships
Morganella morganii has the ability to form partnerships with other species of
bacteria via forming specific interactions. These interactions can include trading metabolites
or exchanging molecular signals [37]. One study found an example of these types of
interactions in M. morganii in which a number of genes were overexpressed when P.
aeruginosa was in the presence of M. morganii during a catheter associated urinary tract
infection (CAUTI) [38]. This study also found that there were several metabolites that were
released by M. morganii such as the siderophores PirA and PfeA that were then taken up by
P. aeruginosa [38]. These siderophores help compensate for the low amount of iron found in
the bladder environment [38]. Subsequently, it was also found that these two bacteria
differed in the carbon sources that they utilized with P. aeruginosa taking up mostly peptides
and amino acids while M. morganii utilized N-acetylglucosamine and urea [38]. This could
indicate that these two species of bacteria are able to coexist in the human gut since they do
not compete for resources. The data acquired from this experiment indicates that interactions
occur between bacteria normally found in the human gut and these interactions may assist
them in causing infection. These partnerships can provide further insight into the role that
certain virulence factors play in causing infections such as urinary tract infections (UTIs).
M. morganii and Urinary Tract Infections
The human gut microbiome has recently gained more attention due to its possible
links to metabolic disorders such as obesity, autoimmune disorders, gastrointestinal
disorders, and stress-related disorders such as depression and anxiety [16,17,19]. The gut
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microbiome gives rise to these disorders through a variety of mechanisms. It is often a
common cause of nosocomial infections due to the fact that they can be opportunistic
pathogens. Urinary tract infections are some of the most common bacterial infections
affecting around 150 million people every year worldwide [39]. One of the most common
healthcare acquired infections are CAUTIs [40]. In addition, indwelling catheter use was
also one of the most common causes of secondary bloodstream infections with the chances
of being infected with bacteremia increasing the longer the catheter stays in place [40].
Urinary tract infections typically begin when uropathogenic bacteria that initially
reside in the gut begin to colonize the urethra and then move to the bladder [39]. They
accomplish this by expressing specific virulence factors that allow them to thrive in the
urinary tract. Two of the most prominent virulence factors that are expressed during UTIs
are bacterial adhesins and the presence of the urease gene [39]. Adhesins allow bacteria to
adhere to the epithelium of the bladder thereby being able to colonize it [39]. The urease
gene allows uropathogenic bacteria to utilize urea as a nitrogen source, thereby allowing
them to grow and form biofilms during UTIs [39]. In addition, it has been found that the
urease gene plays a prominent role in polymicrobial associated CAUTI [41]. Therefore,
bacteria residing in the gut are a critical targeting point for the treatment of urinary tract
infections. With this being said, it becomes increasingly important to study adaptation
mechanisms of bacteria that normally colonize the human gut such as M. morganii.
M. morganii drug resistance
Morganella morganii was included in the group of Enterobacteriacea that were
deemed by the World Health Organization (WHO) to be of critical importance due to their
increasing resistance to antibiotics [42]. On a molecular level, there have been several drug
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resistance genes detected in M. morganii against β-lactams, aminoglycosides, phenicols,
macrolides ERY, tetracycline, trimethoprim, and fluoroquinolones [28]. However, M.
morganii is able to form partnerships with other species of bacteria such as P. aeruginosa, a
species also considered to be critically important by the WHO due to it becoming
increasingly antibiotic resistant [42]. It has mostly acquired this resistance through horizontal
gene transfer as well as through chromosomal mutations [43]. Since M. morganii has a close
partnership with P. aeruginosa, it is possible that it has gained even more drug resistance
genes via horizontal transfer. Therefore, M. morganii should be considered an emerging
threat. This study will thus create a basic molecular metabolic and drug resistance profile for
a relatively unknown organism that has the potential to cause widespread damage especially
in the hospital setting.
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METHODS
M. morganii culturing
The Morganella morganii subsp. morganii M1 strain (ATCC 23585) was purchased from
the American Type Culture Collection (ATCC): The Global Bioresource Center website.
These strains are maintained as glycerol stocks (80% v/v glycerol) and stored in the -80°C
freezer. Starting cultures for growth or protein expression experiments are prepared 12-14
hours prior to the experiment by inoculating bacteria from the stock solution into a tube
containing 3 mL of lysogeny broth (LB). The bacteria are then allowed to grow in a Thermo
Scientific MaxQ600 shaking incubator for 12-14 hours at a temperature of 37ºC.
Preparation of carbon sources
In order to assess differences in metabolic activity, a variety of carbon sources were
prepared. These carbon sources were first dissolved in their respective solvent, either
autoclaved millipore water, sodium hydroxide (NaOH), or hydrochloric acid (HCl). The
stock solutions prepared were either 5%, 10%, 25%, or 60% w/v depending on their
respective solubilities. Once the carbon sources were fully dissolved, they were filter
sterilized and stored according to manufacturer's instructions.
Growth experiments
In order to assess the growth of M. morganii under different metabolites, growth
experiments were conducted. In order to conduct the growth experiments, a yeast minimal
media (20 g NaCl and 2 g of yeast extract per 1 L of water) was used to evaluate the effect of
different carbon sources on the growth of M. morganii [44]. Growth curves were conducted
over an 8-hour period with measurements being taken in 30 minute intervals. The stock
solutions of carbon sources that were previously prepared were used. In addition, the carbon
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sources were diluted to 0.4%. A VWR UV-3100 PC spectrophotometer was used to take the
absorbance measurements and to obtain the optical density (OD) at each interval. The
starting OD600 of each growth curve was adjusted to 0.01. In order to construct the growth
curve, the OD600 was plotted against time using a logarithmic scale. In the growth curves, a
higher OD600 indicated a higher concentration of bacteria and therefore more growth. The
control for this experiment was the growth curve constructed when M. morganii is grown
using only the yeast minimal media with no supplemental carbon source. Using data obtained
from these experiments, a panel was created for metabolized and categorized as effectively
taken up, not utilized, or toxic to M. morganii.
Heat map experiments
After evaluation of growth differences and a cross-examination with the bioinformatics
analysis conducted on M. morganii, it was found that two carbon sources that were supposed
to be utilized by our bacterium due to the fact that it had the necessary genetic machinery,
were not being used. These two carbon sources were urea and ethanolamine. Morganella
morganii was found to contain a urease gene cluster along with a urea transporter and an
ethanolamine utilization (eut) operon. Therefore, literature research was conducted and it was
determined that urea was only utilized when phosphate was also present and ethanolamine
was only utilized when cobalamin (vitamin B12) was also present [45,46]. Therefore, a heat
map was constructed in which different concentrations of both urea and ethanolamine were
supplied with different concentrations of phosphate and vitamin B12, respectively. The urea
and phosphate experiments were done on 96 well-plates with the concentrations of both urea
and phosphate being 0%, 0.01%, 0.02%, 0.04%, 0.08%, 0.16%, 0.32%, and 0.64%.
Morganella morganii was grown using different concentrations of both urea and phosphate
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along with yeast minimal media that added up to a final volume of 300 µl. Morganella
morganii was then grown for 8 hours using the Tecan Infinite M Nano 200 Pro Microplate
Reader with absorbance values being taken every 30 minutes. In addition, a heat map was
constructed for the utilization of ethanolamine and vitamin B12 by M. morganii by growing
our bacterium in varying concentrations of these two carbon sources. The concentrations for
ethanolamine used were 0%, 0.01%, 0.02%, 0.04%, 0.08% 0.16%, 0.32%, 0.64%, and 1.28%
with the concentrations of vitamin B12 being 0, 0.01 mM, 0.02 mM, 0.04 mM, 0.08 mM,
0.16 mM, 0.32 mM, 0.64 mM, 1.28 mM, and 2.56 mM. Morganella morganii was grown
using different concentrations of both ethanolamine and vitamin B12 along with yeast
minimal media that added up to a final volume of 3 mL. The absorbance values were taken at
the end of an 8-hour growth period and these values were converted to optical density.
Protein expression profiles
In order to evaluate protein expression, sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) was used. The bacteria was allowed to grow to an OD600 of 0.3
because it is when they have reached mid-log phase and are considered to be the most
metabolically active [47]. The samples were then prepared by using an OD600 of 0.50. These
samples were centrifuged at 13000 rpm for 2 minutes and the supernatant decanted. The
samples were then resuspended in 15 µl of loading dye and 15 µl of distilled (DI) water.
Then 20 µl of the samples were loaded into the wells together with 2.5 µl of the protein
ladder.
Bioinformatics analysis of M. morganii genes
A bioinformatics approach will be used in order to create a list of genes found in M.
morganii. The fully sequenced genome of M. morganii KT will first be downloaded from the
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National Center for Biotechnology Information (NCBI) database. Since around 22% of its
genome codes for hypothetical proteins, the Federal Acquisition Streamlining Act (FASTA)
sequences of these proteins will be evaluated using the Basic Local Alignment Search Tool
(BLAST). This created a more definitive list for the function of M. morganii’s genes by
finding putative functions based on a similarity search. After this list was created, any genes
involved in the metabolism of M. morganii will be highlighted using the information
gathered from the growth experiments.
Bioinformatic construction of metabolic pathways
Once it was determined which carbon sources were shown to give M. morganii a growth
advantage, the general metabolic pathways known to break down these carbon sources in M.
morganii were searched for in the Kyoto Encyclopedia of Genes and Genomes (KEGG). A
comprehensive list of all the enzymes that make up these metabolic pathways were then put
together. If a pathway for a carbon source was not specifically found in M. morganii, then the
general metabolic pathway for that carbon source was used to calculate which genes coded
for the enzymes involved in that pathway. These genes were then cross referenced with the
gene list that was downloaded from the NCBI database for M. morganii and that was
completed using the BLAST function. If the genes were found in M. morganii then they were
used to make the metabolic map for that particular carbon source. If a specific gene was not
found for a metabolic enzyme, then it was listed as “hypothetical protein” in the metabolic
map.
Disk diffusion assays
In order to assess which antibiotics M. morganii was resistant to, disc diffusion assays
were conducted. The antibiotics tested were chosen according to the performance standards
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for antimicrobial susceptibility testing set forth by the Clinical and Laboratory Standards
Institute (CLSI) for bacteria belonging to the Enterobacteriaceae family. Stock solutions of
all of the antibiotics were made and filter sterilized. Morganella morganii was grown
overnight for 12-14 hours. Then, M. morganii was diluted to an OD of 0.01 before it was
allowed to grow to mid-log phase or an OD of 0.5. While our bacteria grew, we diluted the
stock solutions of our antibiotics to a final concentration that would allow us to follow the
disk content guidelines outlined in the performance standards for antimicrobial susceptibility
testing created by the CLSI. In addition, while our bacteria grew, we prepared a 10% agar
solution and autoclaved it. 30 minutes before our bacteria finished growing, we added 20 µl
of our diluted solutions to our disks and allow them to dry. Once the bacteria had grown to
mid-log phase or an OD of 0.5, 2 mL were added to 4 mL of our agar solution and this
solution was added to a Mueller-Hinton II agar plate. The agar was left to solidify for 1
minute before the disks were placed on it. These plates were then allowed to incubate at 35°C
for 16-18 hours. After incubation, the zones of inhibition were measured and these values
were used to determine the interpretative categories and the interpretative minimal inhibitory
concentrations (MIC) created by the CLSI. The interpretative categories were susceptible (S),
susceptible-dose dependent (SDD), intermediate (I), and resistant (R).
Statistical analysis
In order to determine which metabolites were effectively taken up by M. morganii, a twoway analysis of variance (ANOVA) was performed using the GraphPad Prism Software.
More specifically, a Dunnett’s multiple comparisons test was performed in order to compare
the OD values from our control growth curve with the growth curves of our carbon sources.
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RESULTS
Growth curves
Growth curves were conducted using the carbon sources that we prepared in the
laboratory. The concentrations of the stock solutions for these carbon sources ranged from
5% to 60%. However, these solutions were further diluted to a concentration of 0.4%.
Preliminary tests were conducted in order to determine the concentration that we would
dilute each carbon source to in order to maintain the same concentration throughout all of our
growth experiments. In addition, each growth experiment was repeated twice. Therefore,
each point from our growth curves shows the mean of our two data sets at that specific time
interval, and the error bars show the standard deviation between our two trials.

Figure 2. Hexose sugars. Growth curves conducted on M. morganii using hexose sugars.
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According to Table 1, the only carbon sources from the hexose group shown in Figure 2 that
were statistically significant from the control were mannose, galactose, glucose, and fructose.
In addition, these carbon sources were shown to give M. morganii a growth advantage.
Mannose and galactose are both epimers of glucose meaning that they only differ in
configuration around one carbon atom. Therefore, it is not surprising that these two carbon
sources were metabolized by M. morganii. Fructose differs more in structure from glucose
since it is a ketose instead of an aldose but much like mannose, galactose, and glucose, it is
still a very common and abundant sugar found in the gut [51].

Figure 3. Pentose sugars. Growth curves conducted on M. morganii using pentose sugars.
According to Table 1, the only carbon sources from the pentose group shown in Figure 3
that were statistically significant from the control were xylose and ribose. In addition, these
carbon sources were shown to give M. morganii a growth advantage. Xylose and ribose are
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both carbon sources that are found in the human gut. Xylose is an exogenous carbon source
since it is mainly ingested as part of our daily diets in the form of sweeteners [53]. Ribose on
the other hand is an endogenous carbon source that is present in the gut due to RNA
degradation [52]. Both of these carbon sources are therefore abundant in the GI tract.

Figure 4. Alcohol sugars. Growth curves conducted on M. morganii using alcohol sugars.
According to Table 1, the only carbon sources from the alcohol sugars group shown in
Figure 4 that were statistically significant from the control group were xylitol and glycerol.
In addition, these carbon sources were shown to give M. morganii a growth advantage.
Xylitol is an exogenous carbon source because it is mainly used as a food additive in the
form of sweeteners and it is naturally found in many fruits and vegetables [54]. On the other
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hand, glycerol is considered an endogenous carbon source due to the fact that it appears in
the gut when fatty acids are broken down into their component parts.
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Figure 5. Sugar acids. Growth curves conducted on M. morganii using sugar acids.
According to Table 1, all of the carbon sources belonging to the sugar acids group shown in
Figure 5 were statistically significant from our control. However, out of the two carbon
sources, only gluconic acid provided M. morganii with a growth advantage. D-glucuronic
acid was shown to be toxic to M. morganii. This was especially surprising because both of
these carbon sources are very similar in structure, yet they have complete opposite effects
when it comes to helping M. morganii grow. Gluconic acid is considered an exogenous
carbon source because it is mainly found as a chemical present in fruit, honey, and wine [56].
Therefore, gluconic acid is a very common carbon source that is present in our everyday
diets.
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Figure 6. Amino sugars. Growth curves conducted on M. morganii using amino sugars.
According to Table 1, all of the carbon sources belonging to the amino sugars group shown
in Figure 6 were shown to be statistically significant from the control. However, only Nacetylglucosamine and D-glucosamine provided M. morganii with a growth advantage. Nacetylneuraminic acid, also named sialic acid, was shown to be toxic to M. morganella. Nacetylglucosamine and D-glucosamine are less common sugars found in the gut since they
are mostly exogenous carbon sources that enter the gut environment via supplements aimed
at improving joint health [55]. On the other hand, it was surprising that N-acetylneraminic
acid was toxic to M. morganii due to the fact that this carbon source is found attached to
mucins that make up the mucosal layer in the gastrointestinal tract where our bacterium
resides [8]. Therefore, its inability to utilize this carbon source that is abundant in the human
gut must mean that it utilizes an alternative carbon source that might not be used by other
commensal species of bacteria.
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Figure 7. SCFAs. Growth curves conducted on M. morganii using short chain fatty acids.
According to Table 1, none of the short chain fatty acids shown in Figure 7 were shown to
be statistically significant from the control. Even though they did not provide M. morganii
with a growth advantage, they were not shown to be toxic to our organism. Therefore, this
could possibly mean that our bacterium is still able to use these carbon sources, but they do
not provide a growth advantage individually. Since these short chain fatty acids are very
abundant in the human gut, it is possible that it utilizes each of them and all three of them
collectively offer a growth advantage. Also, these short chain fatty acids have very similar
structures, so if they are able to be uptaken by M. morganii they probably share the same
cellular transporter. This can be tested for using protein expression experiments. If the same
protein is expressed when M. morganii is exposed to acetate, propionate, and butyrate, then
this will strongly indicate that they share the same transporter and even the same metabolic
enzymes to break apart these carbon sources.
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Figure 8. Nucleoside sugars. Growth curves conducted on M. morganii using nucleoside
sugars.
According to Table 1, all of the nucleoside sugars shown in Figure 8 were shown to be
statistically significant from our control. However, only thymidine and inosine provided M.
morganii with a growth advantage. Adenosine was shown to be toxic to M. morganii. These
nucleosides provide M. morganii with a growth advantage by being able to be converted into
nucleotides that our bacterium can use for DNA synthesis. If it is able to make more of these
nucleotides, then that means that it will be able to undergo cellular division more often. As a
result, we will notice a growth advantage in our organism, as we did, because the more our
bacterium divides, then the higher the cell count. In our growth experiments, we measured
this cell count by using optical density. The higher the optical density, then the higher the cell
count. Therefore, a high optical density compared to the control indicates that a particular
carbon source offered M. morganii a growth advantage.
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Figure 9. Acids. Growth curves conducted on M. morganii using acids.
According to Table 1, out of the acids shown in Figure 9, L-malic acid, L-maleic acid, and
ascorbic acid were shown to be statistically significant from the control. In addition, these
three acids were shown to be toxic to M. morganii. L-malic and L-maleic acid are very
similar in structure, so it is not surprising that they have the same effect on M. morganii.
However, ascorbic acid, also known as vitamin C, is a fairly common water soluble vitamin
that is found in many food products as well as being sold as a dietary supplement. Due to
ascorbic acid being a very common vitamin, it was very surprising to find that our organism
would not survive when it was placed in an environment with this carbon source. In addition,
lactate which is a very common organic molecule produced by all tissues in the body and
citric acid which is naturally found in citrus fruits, were not shown to provide M. morganii
with a growth advantage. Again, this could be because although these carbon sources are
abundant in the gut, M. morganii could use alternative carbon sources.
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Figure 10. Polysaccharides. Growth curves conducted on M. morganii using
polysaccharides.
According to Table 1, both polysaccharides shown in Figure 10 were statistically significant
from the control. In this case, both of the carbon sources provided M. morganii with a growth
advantage. Both starch and dextrin are composed of glucose molecules and we saw in Figure
2, glucose does provide M. morganii with a significant growth advantage. Therefore, it
makes sense that these polysaccharides provide our bacterium with a significant growth
advantage. In addition, these two carbon sources are abundant in the human gut and are
considered exogenous carbon sources. These two carbon sources are mostly supplied in our
everyday diets because they are found in many plant-based foods such as fruits and
vegetables. The fact that it is able to uptake these polysaccharides could mean that M.
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morganii has the genetic machinery to not only transport these carbon sources into the cell
but also break them apart once inside.

Figure 11. Disaccharides. Growth curves conducted on M. morganii using disaccharides.
According to Table 1, none of the disaccharides shown in Figure 11 were statistically
significant from the control. It was surprising that none of the disaccharides listed here
provided M. morganii with a growth advantage because these carbon sources are all
composed of glucose molecules that are bonded via different glycosidic linkages. Therefore,
it is possible that these disaccharides are not taken up or utilized by M. morganii because
these disaccharides are further broken down by either other species of bacteria that also
reside in the human gut or by human enzymes. This would bypass M. morganii’s need to
break apart these disaccharides into their corresponding monosaccharide units.
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Figure 12. Trisaccharides. Growth curves conducted on M. morganii using trisaccharides.

Figure 13. Glycosides. Growth curves conducted on M. morganii using glycosides.
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Figure 14. Fructans. Growth curves conducted on M. morganii using fructans.

Figure 15. Dietary amino acids. Growth curves conducted on M. morganii using dietary
amino acids.

29

According to Table 1, none of the carbon sources belonging to the trisaccharides, glycosides,
fructans, and dietary amino acid groups shown in Figure 12, Figure 13, Figure 14, and
Figure 15 were shown to be statistically significant from our control. The carbon sources,
raffinose, salicin, inulin, citrulline, and ornithine are less common sugars that our found in
the gut because they are not abundantly supplied in the diet. As a result, it is possible that
many bacteria belonging to the human gut microbiota, including M. morganii, have not quite
adapted to these more exotic sugars.

Figure 16. Essential amino acids. Growth curves conducted on M. morganii using 18
essential amino acids.
According to Table 1, out of all of the essential amino acids shown in Figure 16, serine,
histidine, methionine, glutamine, proline, threonine, phenylalanine, and the casamino acids
which consists of a mixture of all of the essential amino acids excluding tryptophan, provided
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M. morganii with a growth advantage. Arginine, tryptophan, aspragine, aspartic acid,
isoleucine, and cysteine were shown to be toxic to our organism. We did not see a particular
pattern when it came to which type of amino acids M. morganii was able to utilize. For
instance, the polarity of the amino acids does not seem to be a factor when it comes to
deciding which amino acids to utilize because it was able to use up both polar and nonpolar
amino acids. In addition, the presence of an aromatic group also does not seem to be a key
factor because M. morganii is able to utilize phenylalanine, yet tryptophan was toxic to our
organism. Therefore, it is possible that M. morganii contains the genetic machinery to
metabolize only particular amino acids and it could be that it converts amino acids into other
amino acids that it does not necessarily take up from its environment.

Figure 17. Other carbon sources. Growth curves conducted on M. morganii using various
different carbon sources that did not fall under any of the previously listed categories.
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According to Table 1, none of the carbon sources belonging to the other category shown in
Figure 17 were shown to be statistically significant from the control, so they were not shown
to provide M. morganii with a growth advantage.
Statistical analysis
A two-way ANOVA was conducted using all of the OD values we collected as part of
our growth curves. Table 1 shows the results for our two-way ANOVA as well as showing
which carbon sources were significantly different from our control growth curve. Those
carbon sources that were statistically significant were classified as either giving M. morganii
a growth advantage or being toxic to it depending on the OD values collected. These results
are shown in Table 1.
Table 1. Statistical analysis of carbon sources using two-way ANOVA.
Control vs. Carbon Sources

Mean Diff.

Significant?

Adjusted P Value

Control vs. Choline chloride

-0.024

No

0.902

Control vs. Thiosulfate

-0.020

No

0.9802

Control vs. Arabinose

-0.031

No

0.4968

Control vs. Xylose

-0.062

Yes

0.0016

Control vs. Sorbose

-0.031

No

0.5225

Control vs. Xylitol

-0.215

Yes

0.0001

Control vs. Maltitol

-0.009

No

0.9991

Control vs. N-acetylneuraminic acid

0.210

Yes

0.0001

Control vs. Ascorbic acid

0.212

Yes

0.0001

Control vs. Gluconic acid

-0.240

Yes

0.0001

Control vs. Galactose

-0.097

Yes

0.0001
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Table 1. Continued
Control vs. Carbon Sources

Mean Diff.

Significant?

Adjusted P Value

Control vs. Mannose

-0.194

Yes

0.0001

Control vs. N-acetylglucosamine

-0.142

Yes

0.0001

Control vs. L-malic acid

0.207

Yes

0.0001

Control vs. Inulin

-0.034

No

0.3694

Control vs. L-glutamic acid

-0.027

No

0.7407

Control vs. Glycerol

-0.227

Yes

0.0001

Control vs. Citrulline

-0.019

No

0.9836

Control vs. Mannitol

-0.001

No

0.9999

Control vs. Glucose

-0.193

Yes

0.0001

Control vs. Acetate

-0.040

No

0.1519

Control vs. Propionate

-0.042

No

0.1207

Control vs. Butyrate

-0.012

No

0.9988

Control vs. Fructose

-0.141

Yes

0.0001

Control vs. Sorbitol

-0.038

No

0.2103

Control vs. Salicin

0.014

No

0.9985

Control vs. D-glucuronic acid

0.214

Yes

0.0001

Control vs. Ribose

-0.173

Yes

0.0001

Control vs. Inositol

0.003

No

0.9998

Control vs. Maltitol

0.010

No

0.9991

Control vs. D-glucosamine

-0.147

Yes

0.0001

Control vs. Lactulose

0.000

No

0.9999

Control vs. Sucrose

-0.046

No

0.0528

Control vs. Trehalose

-0.007

No

0.9994
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Table 1. Continued
Control vs. Carbon Sources

Mean Diff.

Significant?

Adjusted P Value

Control vs. Lactose

0.014

No

0.9985

Control vs. Maltose

-0.014

No

0.9985

Control vs. Raffinose

-0.007

No

0.9994

Control vs. Lactate

0.004

No

0.9996

Control vs. GABA

0.020

No

0.9814

Control vs. 2-deoxy-D-ribose

0.040

No

0.1622

Control vs. Starch

-0.073

Yes

0.0001

Control vs. Adonitol

-0.042

No

0.1173

Control vs. Rhamnose

-0.042

No

0.1219

Control vs. Arginine

0.212

Yes

0.0001

Control vs. Casamino acids

-0.411

Yes

0.0001

Control vs. L-maleic acid

0.156

Yes

0.0001

Control vs. Fucose

0.005

No

0.9996

Control vs. Dulcitol

0.001

No

0.9999

Control vs. Cellobiose

-0.002

No

0.9999

Control vs. Dextrin

-0.064

Yes

0.001

Control vs. Thymidine

-0.047

Yes

0.0431

Control vs. Adenosine

0.202

Yes

0.0001

Control vs. Serine

-0.149

Yes

0.0001

Control vs. Citric acid

0.001

No

0.9999

Control vs. Histidine

0.051

Yes

0.0206

Control vs. Inosine

-0.138

Yes

0.0001

Control vs. Ornithine

-0.003

No

0.9997
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Table 1. Continued
Control vs. Carbon Sources

Mean Diff.

Significant?

Adjusted P Value

Control vs. Methionine

-0.185

Yes

0.0001

Control vs. Glutamine

-0.052

Yes

0.0165

Control vs. Proline

-0.076

Yes

0.0001

Control vs. Glycine

0.003

No

0.9997

Control vs. Lysine

-0.001

No

0.9999

Control vs. Threonine

-0.146

Yes

0.0001

Control vs. Valine

0.019

No

0.9844

Control vs. Alanine

-0.014

No

0.9985

Control vs. Phenylalanine

-0.048

Yes

0.035

Control vs. Aspartic acid

0.196

Yes

0.0001

Control vs. Tryptophan

0.190

Yes

0.0001

Control vs. Asparagine

0.194

Yes

0.0001

Control vs. Isoleucine

0.189

Yes

0.0001

Control vs. Cysteine

0.187

Yes

0.0001
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Dunnet’s multiple comparisons test was used to find out which carbon sources were shown to
be statistically different from our control growth curve thus indicating that M. morganii
either gains or loses a statistically significant growth advantage. A p-value of 0.05 was used
as a reference value and our statistical analysis was conducted on a program known as
GraphPad Prism. In order to conduct the statistical analysis, the mean of the log OD600 values
for both trials were taken for each carbon source and these values were then compared to the
control.
Table 2. Toxic and growth advantage carbon sources.
Toxic

Growth advantage

N-acetylneuraminic acid

Xylose

Dextrin

Ascorbic acid

Xylitol

Thymidine

L-malic acid

Gluconic acid

Inosine

D-glucuronic acid

Galactose

Serine

L-maleic acid

Mannose

Histidine

Adenosine

N-acetylglucosamine

Proline

Arginine

Glycerol

Threonine

Tryptophan

Glucose

Methionine

Asparagine

Fructose

Glutamine

Aspartic acid

Ribose

Phenylalanine

Isoleucine

D-glucosamine

Casamino acids

Cysteine

Starch
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After conducting our statistical analysis, the carbon sources that were shown to be toxic and
to give M. morganii a growth advantage according to our two-way ANOVA are shown in
Table 2.
Heat map experiments
In order to better assess the growth of M. morganii using both urea and phosphate, a heat
map was arranged using the absorbance values that were collected when our bacterium was
grown for 8 hours under different concentrations of urea and phosphate. Table 3 shows the
values that our microplate was assigned.
Table 3. Set up for heat map experiments.

Phosphate

Urea
0

0.01%

0.02%

0.04%

0.08%

0.16%

0.32%

0.64%

0

1

2

3

4

5

6

7

8

A

0.01%

1

2
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4

5

6

7

8

B

0.02%

1

2

3

4

5

6

7

8

C

0.04%

1

2

3

4

5

6

7

8

D

0.08%

1

2

3

4

5

6

7

8

E

0.16%

1

2

3

4

5

6

7

8

F

0.32%

1

2

3

4

5

6

7

8

G

0.64%

1

2

3

4

5

6

7

8

H

The arrangement for the proceeding urea and phosphate experiments are shown here. There
were a total of 64 growth curves conducted for each trial and two trials were conducted.
Figure 18 and Figure 19 show the results of the actual heat map from the urea and
phosphate experiments.
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Figure 18. Trial 1 for Urea and Phosphate Experiments.
A1 0.096 0.099 0.104 0.113 0.131 0.152 0.167 0.181 0.194 0.212 0.230 0.247 0.262 0.275 0.287 0.298 0.310
A2 0.109 0.113 0.119 0.128 0.138 0.149 0.163 0.181 0.201 0.219 0.234 0.250 0.264 0.278 0.289 0.300 0.311
A3 0.105 0.106 0.113 0.123 0.133 0.143 0.154 0.166 0.184 0.199 0.213 0.228 0.242 0.255 0.265 0.275 0.284
A4 0.104 0.108 0.115 0.126 0.136 0.144 0.154 0.163 0.176 0.190 0.202 0.214 0.226 0.238 0.250 0.260 0.269
A5 0.098 0.106 0.113 0.123 0.131 0.139 0.147 0.156 0.167 0.178 0.189 0.198 0.207 0.217 0.225 0.234 0.243
A6 0.098 0.104 0.114 0.125 0.133 0.138 0.143 0.151 0.158 0.166 0.171 0.178 0.184 0.190 0.196 0.201 0.206
A7 0.089 0.094 0.104 0.112 0.120 0.126 0.133 0.136 0.142 0.151 0.156 0.160 0.161 0.163 0.164 0.166 0.168
A8 0.094 0.097 0.100 0.103 0.106 0.107 0.110 0.108 0.106 0.105 0.103 0.101 0.101 0.101 0.100 0.099 0.099
B1 0.098 0.100 0.106 0.112 0.122 0.130 0.139 0.155 0.175 0.192 0.212 0.233 0.253 0.273 0.290 0.307 0.319
B2 0.099 0.101 0.107 0.115 0.127 0.139 0.152 0.165 0.183 0.199 0.219 0.238 0.255 0.273 0.286 0.302 0.312
B3 0.097 0.100 0.107 0.116 0.128 0.139 0.150 0.162 0.178 0.194 0.212 0.229 0.247 0.264 0.278 0.292 0.301
B4 0.098 0.103 0.109 0.118 0.130 0.141 0.153 0.167 0.187 0.205 0.224 0.243 0.259 0.277 0.292 0.304 0.316
B5 0.092 0.099 0.105 0.112 0.123 0.134 0.147 0.161 0.179 0.197 0.214 0.232 0.248 0.262 0.276 0.288 0.298
B6 0.093 0.099 0.106 0.113 0.123 0.136 0.148 0.160 0.176 0.191 0.207 0.222 0.234 0.247 0.259 0.269 0.277
B7 0.091 0.097 0.103 0.113 0.123 0.132 0.142 0.153 0.160 0.162 0.163 0.165 0.167 0.170 0.171 0.174 0.177
B8 0.093 0.094 0.098 0.102 0.105 0.107 0.110 0.114 0.115 0.115 0.115 0.114 0.115 0.116 0.114 0.115 0.115
C1 0.096 0.103 0.112 0.120 0.128 0.138 0.147 0.155 0.165 0.179 0.201 0.213 0.225 0.236 0.246 0.259 0.271
C2 0.099 0.104 0.111 0.120 0.131 0.140 0.147 0.157 0.165 0.178 0.196 0.212 0.231 0.249 0.263 0.282 0.296
C3 0.095 0.101 0.106 0.115 0.127 0.139 0.148 0.159 0.170 0.186 0.203 0.220 0.237 0.255 0.272 0.287 0.299
C4 0.092 0.099 0.106 0.116 0.128 0.139 0.149 0.162 0.175 0.193 0.211 0.228 0.245 0.262 0.279 0.294 0.308
C5 0.093 0.098 0.105 0.114 0.125 0.137 0.146 0.157 0.168 0.183 0.200 0.214 0.230 0.247 0.259 0.275 0.286
C6 0.091 0.098 0.106 0.117 0.127 0.137 0.146 0.159 0.172 0.187 0.203 0.220 0.236 0.254 0.268 0.282 0.296
C7 0.089 0.094 0.103 0.115 0.128 0.139 0.148 0.160 0.168 0.176 0.183 0.191 0.200 0.210 0.219 0.229 0.236
C8 0.092 0.093 0.099 0.103 0.108 0.110 0.114 0.119 0.122 0.127 0.131 0.134 0.137 0.141 0.142 0.145 0.147
D1 0.100 0.106 0.116 0.124 0.134 0.143 0.153 0.164 0.174 0.184 0.199 0.219 0.234 0.247 0.258 0.271 0.285
D2 0.096 0.103 0.114 0.121 0.129 0.136 0.141 0.148 0.156 0.166 0.179 0.193 0.210 0.229 0.247 0.265 0.280
D3 0.099 0.105 0.114 0.122 0.129 0.136 0.141 0.146 0.154 0.162 0.173 0.186 0.202 0.218 0.236 0.252 0.267
D4 0.100 0.105 0.114 0.120 0.128 0.134 0.140 0.146 0.154 0.164 0.174 0.189 0.205 0.221 0.239 0.254 0.270
D5 0.099 0.104 0.115 0.120 0.127 0.132 0.137 0.142 0.149 0.159 0.168 0.181 0.197 0.213 0.229 0.247 0.263
D6 0.108 0.107 0.115 0.122 0.127 0.132 0.136 0.140 0.147 0.155 0.166 0.177 0.191 0.206 0.221 0.238 0.256
D7 0.104 0.102 0.107 0.116 0.123 0.129 0.133 0.137 0.144 0.151 0.159 0.166 0.172 0.179 0.186 0.194 0.203
D8 0.098 0.106 0.105 0.106 0.107 0.108 0.108 0.109 0.108 0.108 0.113 0.110 0.116 0.116 0.116 0.122 0.119
E1 0.088 0.090 0.093 0.097 0.101 0.106 0.111 0.116 0.120 0.123 0.126 0.129 0.134 0.143 0.151 0.157 0.162
E2 0.091 0.093 0.100 0.110 0.117 0.127 0.138 0.151 0.163 0.175 0.191 0.207 0.223 0.243 0.258 0.276 0.290
E3 0.094 0.097 0.102 0.110 0.117 0.126 0.135 0.147 0.160 0.172 0.185 0.200 0.217 0.234 0.250 0.264 0.276
E4 0.097 0.097 0.100 0.106 0.113 0.120 0.129 0.137 0.149 0.161 0.175 0.188 0.204 0.221 0.237 0.253 0.265
E5 0.087 0.087 0.090 0.095 0.102 0.110 0.117 0.126 0.137 0.152 0.165 0.178 0.194 0.211 0.227 0.243 0.255
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Figure 18. Continued
E6 0.088 0.089 0.092 0.097 0.104 0.111 0.118 0.127 0.138 0.149 0.161 0.174 0.190 0.206 0.224 0.242 0.256
E7 0.091 0.092 0.093 0.097 0.103 0.110 0.115 0.121 0.126 0.133 0.141 0.149 0.157 0.164 0.170 0.180 0.188
E8 0.089 0.094 0.100 0.101 0.102 0.104 0.104 0.105 0.106 0.107 0.108 0.108 0.108 0.108 0.109 0.111 0.109
F1 0.096 0.097 0.099 0.099 0.099 0.102 0.102 0.103 0.104 0.105 0.107 0.107 0.109 0.107 0.105 0.103 0.102
F2 0.091 0.092 0.096 0.098 0.102 0.112 0.120 0.129 0.138 0.148 0.155 0.161 0.166 0.174 0.182 0.191 0.200
F3 0.087 0.090 0.094 0.097 0.102 0.111 0.120 0.130 0.139 0.149 0.158 0.163 0.172 0.181 0.191 0.202 0.216
F4 0.089 0.092 0.095 0.097 0.101 0.110 0.117 0.125 0.134 0.145 0.157 0.166 0.177 0.190 0.200 0.212 0.227
F5 0.084 0.085 0.088 0.089 0.093 0.102 0.112 0.123 0.133 0.143 0.154 0.164 0.175 0.187 0.198 0.211 0.225
F6 0.087 0.090 0.089 0.090 0.094 0.100 0.108 0.119 0.130 0.140 0.147 0.155 0.165 0.177 0.191 0.206 0.221
F7 0.103 0.104 0.107 0.108 0.109 0.113 0.117 0.125 0.133 0.142 0.147 0.152 0.158 0.166 0.176 0.190 0.202
F8 0.086 0.090 0.094 0.095 0.096 0.098 0.098 0.099 0.100 0.101 0.102 0.102 0.104 0.107 0.107 0.109 0.111
G1 0.090 0.092 0.093 0.094 0.094 0.095 0.094 0.096 0.095 0.096 0.097 0.099 0.100 0.099 0.098 0.097 0.096
G2 0.100 0.097 0.097 0.098 0.098 0.098 0.097 0.099 0.098 0.098 0.100 0.102 0.102 0.101 0.101 0.103 0.105
G3 0.097 0.097 0.096 0.096 0.095 0.095 0.096 0.097 0.097 0.098 0.099 0.101 0.103 0.104 0.106 0.108 0.108
G4 0.090 0.090 0.090 0.091 0.091 0.093 0.093 0.094 0.095 0.097 0.098 0.101 0.101 0.103 0.105 0.107 0.108
G5 0.089 0.089 0.088 0.089 0.091 0.091 0.093 0.095 0.097 0.098 0.101 0.102 0.104 0.108 0.110 0.112 0.114
G6 0.094 0.097 0.095 0.094 0.095 0.096 0.098 0.100 0.101 0.102 0.104 0.107 0.109 0.112 0.114 0.117 0.121
G7 0.092 0.094 0.095 0.097 0.098 0.098 0.098 0.099 0.099 0.100 0.104 0.105 0.106 0.111 0.112 0.114 0.116
G8 0.096 0.096 0.096 0.098 0.098 0.098 0.099 0.100 0.098 0.096 0.095 0.094 0.094 0.094 0.094 0.094 0.094
H1 0.103 0.105 0.105 0.104 0.104 0.104 0.103 0.103 0.102 0.102 0.103 0.102 0.102 0.103 0.102 0.102 0.101
H2 0.100 0.104 0.104 0.103 0.102 0.101 0.099 0.098 0.097 0.095 0.094 0.093 0.093 0.093 0.093 0.093 0.092
H3 0.103 0.105 0.102 0.102 0.100 0.100 0.098 0.097 0.097 0.095 0.095 0.094 0.093 0.093 0.093 0.092 0.091
H4 0.104 0.104 0.103 0.106 0.104 0.102 0.101 0.100 0.099 0.098 0.097 0.097 0.095 0.094 0.095 0.095 0.094
H5 0.097 0.097 0.097 0.097 0.096 0.095 0.095 0.094 0.093 0.092 0.092 0.091 0.092 0.091 0.091 0.092 0.090
H6 0.099 0.102 0.099 0.098 0.096 0.094 0.096 0.093 0.093 0.092 0.092 0.092 0.092 0.091 0.092 0.091 0.091
H7 0.099 0.101 0.099 0.098 0.095 0.094 0.093 0.093 0.092 0.093 0.091 0.091 0.091 0.092 0.092 0.091 0.091
H8 0.092 0.092 0.093 0.093 0.093 0.093 0.094 0.093 0.093 0.093 0.093 0.093 0.093 0.093 0.093 0.093 0.093

Figure 18. Trial 1 for Urea and Phosphate Experiments. Shown in the table are the
absorbance values for the first trial of our urea and phosphate experiments. The blue values
indicate little to no growth while the red values indicate growth of M. morganii under the
corresponding conditions. Each column corresponds to a different time interval and in these
experiments the time intervals were taken every 30 minutes.
Both trials for the urea and phosphate experiments were conducted using different bacterial
starting cultures in order to get accurate duplicates. However, both starting cultures were
initially diluted to an OD600 of 0.01 in order to keep our results consistent.
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Figure 19. Trial 2 for Urea and Phosphate Experiments
A1 0.097 0.100 0.104 0.108 0.122 0.141 0.163 0.179 0.191 0.203 0.217 0.231 0.240 0.252 0.262 0.275 0.289
A2 0.101 0.103 0.108 0.114 0.123 0.138 0.155 0.171 0.189 0.206 0.221 0.236 0.249 0.260 0.271 0.282 0.293
A3 0.100 0.103 0.112 0.117 0.125 0.136 0.153 0.170 0.187 0.203 0.218 0.233 0.246 0.258 0.268 0.279 0.289
A4 0.102 0.105 0.113 0.119 0.128 0.139 0.148 0.162 0.179 0.194 0.211 0.228 0.241 0.254 0.263 0.275 0.284
A5 0.103 0.104 0.109 0.117 0.125 0.133 0.141 0.149 0.159 0.169 0.178 0.189 0.199 0.212 0.225 0.234 0.243
A6 0.103 0.106 0.115 0.121 0.126 0.130 0.133 0.138 0.142 0.148 0.153 0.157 0.161 0.165 0.170 0.174 0.178
A7 0.103 0.102 0.108 0.116 0.123 0.126 0.130 0.135 0.138 0.145 0.150 0.152 0.153 0.156 0.156 0.157 0.157
A8 0.098 0.100 0.103 0.106 0.111 0.117 0.119 0.122 0.123 0.126 0.126 0.128 0.127 0.129 0.130 0.129 0.128
B1 0.096 0.099 0.103 0.109 0.117 0.128 0.143 0.159 0.177 0.193 0.205 0.218 0.233 0.244 0.261 0.271 0.282
B2 0.097 0.098 0.103 0.107 0.116 0.130 0.147 0.164 0.183 0.199 0.215 0.232 0.247 0.264 0.281 0.292 0.302
B3 0.100 0.100 0.105 0.109 0.118 0.131 0.146 0.161 0.179 0.195 0.208 0.224 0.240 0.255 0.267 0.281 0.290
B4 0.113 0.100 0.107 0.115 0.126 0.137 0.153 0.167 0.185 0.202 0.213 0.227 0.241 0.261 0.271 0.284 0.292
B5 0.097 0.097 0.105 0.110 0.120 0.133 0.148 0.163 0.182 0.197 0.211 0.227 0.242 0.257 0.269 0.281 0.290
B6 0.102 0.100 0.105 0.113 0.123 0.133 0.143 0.154 0.165 0.181 0.194 0.209 0.219 0.231 0.242 0.252 0.260
B7 0.095 0.098 0.103 0.113 0.121 0.131 0.138 0.145 0.151 0.155 0.154 0.154 0.155 0.156 0.157 0.157 0.159
B8 0.095 0.096 0.099 0.102 0.106 0.112 0.118 0.124 0.132 0.141 0.150 0.157 0.163 0.167 0.169 0.171 0.173
C1 0.098 0.101 0.106 0.112 0.120 0.128 0.134 0.141 0.147 0.159 0.183 0.203 0.218 0.231 0.243 0.252 0.265
C2 0.099 0.105 0.110 0.114 0.122 0.132 0.140 0.146 0.156 0.167 0.179 0.194 0.208 0.224 0.238 0.251 0.267
C3 0.100 0.105 0.109 0.114 0.122 0.134 0.149 0.160 0.174 0.189 0.205 0.225 0.240 0.256 0.272 0.282 0.293
C4 0.100 0.102 0.108 0.112 0.121 0.131 0.143 0.155 0.167 0.180 0.193 0.207 0.224 0.240 0.251 0.267 0.278
C5 0.097 0.101 0.107 0.113 0.119 0.129 0.140 0.148 0.161 0.175 0.188 0.201 0.214 0.230 0.243 0.258 0.271
C6 0.096 0.098 0.102 0.108 0.116 0.124 0.135 0.145 0.157 0.169 0.184 0.196 0.209 0.223 0.236 0.250 0.261
C7 0.101 0.100 0.103 0.108 0.116 0.123 0.130 0.137 0.145 0.154 0.161 0.167 0.169 0.173 0.177 0.181 0.184
C8 0.099 0.098 0.099 0.099 0.101 0.104 0.108 0.113 0.117 0.123 0.132 0.140 0.150 0.160 0.166 0.172 0.178
D1 0.108 0.108 0.112 0.119 0.126 0.131 0.136 0.141 0.148 0.157 0.166 0.178 0.195 0.210 0.220 0.230 0.239
D2 0.105 0.105 0.109 0.115 0.123 0.131 0.138 0.142 0.147 0.155 0.164 0.174 0.187 0.201 0.216 0.232 0.248
D3 0.103 0.105 0.111 0.116 0.122 0.130 0.140 0.148 0.157 0.167 0.180 0.193 0.209 0.224 0.236 0.253 0.263
D4 0.120 0.109 0.115 0.124 0.131 0.137 0.149 0.156 0.166 0.179 0.194 0.205 0.217 0.236 0.247 0.262 0.269
D5 0.109 0.106 0.111 0.117 0.125 0.132 0.139 0.144 0.151 0.160 0.170 0.183 0.195 0.210 0.225 0.241 0.252
D6 0.101 0.102 0.107 0.112 0.118 0.121 0.126 0.133 0.141 0.148 0.158 0.166 0.176 0.190 0.202 0.216 0.230
D7 0.103 0.100 0.101 0.105 0.112 0.118 0.123 0.128 0.136 0.145 0.156 0.163 0.171 0.177 0.187 0.196 0.205
D8 0.092 0.096 0.098 0.099 0.101 0.103 0.107 0.111 0.117 0.122 0.128 0.137 0.146 0.155 0.159 0.164 0.168
E1 0.099 0.099 0.099 0.102 0.106 0.110 0.115 0.120 0.125 0.130 0.133 0.137 0.140 0.140 0.142 0.144 0.146
E2 0.099 0.103 0.104 0.110 0.117 0.124 0.130 0.139 0.151 0.160 0.172 0.182 0.198 0.213 0.227 0.240 0.253
E3 0.100 0.103 0.104 0.109 0.119 0.126 0.136 0.150 0.159 0.170 0.183 0.198 0.213 0.228 0.237 0.251 0.261
E4 0.100 0.100 0.102 0.103 0.112 0.116 0.124 0.134 0.146 0.155 0.165 0.179 0.193 0.209 0.221 0.234 0.249
E5 0.093 0.096 0.096 0.098 0.102 0.109 0.117 0.125 0.138 0.150 0.160 0.172 0.186 0.202 0.218 0.232 0.242
E6 0.089 0.091 0.093 0.096 0.103 0.110 0.116 0.123 0.131 0.142 0.154 0.165 0.180 0.192 0.207 0.223 0.239
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Figure 19. Continued
E7 0.088 0.087 0.091 0.093 0.100 0.105 0.112 0.120 0.126 0.134 0.143 0.152 0.159 0.167 0.176 0.187 0.198
E8 0.104 0.107 0.107 0.106 0.106 0.106 0.105 0.106 0.104 0.104 0.106 0.106 0.106 0.106 0.107 0.107 0.107
F1 0.107 0.104 0.104 0.104 0.104 0.106 0.107 0.108 0.110 0.113 0.113 0.113 0.114 0.112 0.111 0.109 0.107
F2 0.100 0.098 0.098 0.099 0.100 0.105 0.108 0.113 0.118 0.124 0.131 0.138 0.147 0.155 0.165 0.176 0.187
F3 0.093 0.093 0.094 0.096 0.097 0.100 0.106 0.110 0.117 0.126 0.139 0.149 0.161 0.171 0.184 0.194 0.205
F4 0.095 0.095 0.097 0.098 0.099 0.104 0.109 0.115 0.122 0.132 0.142 0.155 0.167 0.179 0.191 0.202 0.213
F5 0.091 0.090 0.092 0.094 0.094 0.098 0.101 0.108 0.116 0.125 0.138 0.152 0.163 0.176 0.188 0.200 0.214
F6 0.087 0.088 0.090 0.091 0.095 0.096 0.099 0.103 0.108 0.115 0.122 0.133 0.144 0.153 0.163 0.175 0.189
F7 0.087 0.087 0.088 0.091 0.092 0.095 0.097 0.098 0.100 0.103 0.106 0.110 0.116 0.123 0.130 0.137 0.142
F8 0.086 0.087 0.089 0.091 0.093 0.095 0.097 0.098 0.100 0.101 0.102 0.103 0.105 0.105 0.105 0.104 0.104
G1 0.106 0.104 0.102 0.102 0.101 0.101 0.101 0.100 0.100 0.100 0.100 0.101 0.101 0.101 0.101 0.098 0.096
G2 0.110 0.112 0.107 0.104 0.104 0.103 0.102 0.101 0.102 0.100 0.100 0.101 0.100 0.101 0.101 0.101 0.101
G3 0.106 0.103 0.100 0.100 0.098 0.098 0.097 0.097 0.098 0.096 0.097 0.098 0.097 0.098 0.100 0.101 0.101
G4 0.105 0.102 0.101 0.100 0.100 0.099 0.097 0.097 0.099 0.098 0.098 0.100 0.097 0.098 0.100 0.103 0.103
G5 0.103 0.105 0.101 0.101 0.099 0.100 0.099 0.098 0.097 0.098 0.097 0.096 0.095 0.096 0.098 0.098 0.100
G6 0.101 0.102 0.101 0.100 0.100 0.099 0.099 0.099 0.098 0.098 0.098 0.098 0.098 0.099 0.101 0.103 0.104
G7 0.094 0.096 0.096 0.096 0.096 0.096 0.095 0.096 0.096 0.097 0.097 0.097 0.098 0.100 0.101 0.102 0.104
G8 0.096 0.096 0.097 0.095 0.097 0.096 0.096 0.096 0.097 0.097 0.098 0.098 0.098 0.099 0.099 0.098 0.097
H1 0.092 0.091 0.093 0.091 0.092 0.093 0.092 0.092 0.092 0.092 0.092 0.092 0.093 0.093 0.093 0.093 0.093
H2 0.094 0.093 0.096 0.093 0.093 0.093 0.094 0.094 0.095 0.095 0.095 0.095 0.095 0.096 0.097 0.097 0.095
H3 0.094 0.094 0.091 0.091 0.091 0.092 0.092 0.093 0.093 0.093 0.093 0.094 0.094 0.094 0.094 0.094 0.093
H4 0.104 0.107 0.105 0.100 0.098 0.098 0.099 0.098 0.098 0.099 0.099 0.097 0.097 0.097 0.097 0.097 0.097
H5 0.090 0.092 0.090 0.090 0.090 0.090 0.091 0.090 0.091 0.090 0.091 0.091 0.090 0.092 0.091 0.091 0.090
H6 0.090 0.090 0.090 0.091 0.090 0.091 0.092 0.091 0.092 0.092 0.091 0.092 0.092 0.093 0.092 0.093 0.091
H7 0.091 0.091 0.090 0.091 0.089 0.090 0.089 0.089 0.088 0.088 0.089 0.090 0.090 0.090 0.090 0.089 0.089
H8 0.101 0.098 0.098 0.099 0.098 0.097 0.095 0.094 0.093 0.093 0.093 0.092 0.091 0.091 0.091 0.091 0.091

Figure 19. Trial 2 for Urea and Phosphate Experiments. Shown in the figure are the
absorbance values for the second trial of our urea and phosphate experiments. The blue
values indicate little to no growth while the red values indicate growth of M. morganii under
the corresponding conditions. Each column corresponds to a different time interval and in
these experiments the time intervals were 30 minutes.
The urea and phosphate experiments conducted show a prominent pattern. It shows that the
there is little to no growth when 0.64% of urea is added to any amount of phosphate. In
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addition, there is little to no growth as indicated by the blue color in the heat map when we
added 0.32% and 0.64% of phosphate to any amount of urea. Therefore, we found that most
growth occurred when the concentration of urea was between 0% and 0.32% and the
concentration of phosphate was between 0% and 0.16%. These experiments indicate that urea
and phosphate are both needed in order for urea to be transported into M. morganii since it
contains the gene for the urea transporter and for it to be further metabolized [27].
In addition to the urea and phosphate heat map, we also created a heat map for ethanolamine
and vitamin B12. For these experiments, the final optical density values after allowing
ethanolamine and vitamin B12 to grow for 8 hours were used to create the heat maps.

Vitamin B12

0
.01 mM
.02 mM
.04 mM
.08 mM
.16 mM
.32 mM
.64 mM
1.28 mM
2.56 mM

Ethanolamine
0 0.01% 0.02% 0.04% 0.08% 0.16% 0.32% 0.64% 1.28%
0.34 0.116
0 0.044
0
0
0
0
0
0.34 0.348 0.012 0.076
0
0
0
0
0
0.332 0.376
0
0
0
0
0
0
0
0.324 0.052 0.016 0.004 0.008 0.004 0.004 0.004 0.004
0.38 0.38 0.028 0.024 0.024 0.0258 0.024 0.024 0.024
0.456 0.096
0.1 0.168 0.072 0.072 0.068 0.076 0.076
0.496 0.196
0.3 0.16 0.152 0.168 0.132 0.144 0.152
0.596 0.356 0.332
0.3 0.312 0.308 0.296 0.328 0.34
0.928 0.624 0.568 0.552 0.592 0.56 0.512 0.528 0.552
0.952 0.624 0.688 0.672 0.632 0.632 0.56 0.592 0.68

Figure 20. Trial 1 for Ethanolamine and Vitamin B12 Experiments. Shown in the figure
are the optical density values for the first trial in our ethanolamine and vitamin B12
experiments. The blue values indicate little to no growth while the red values indicate growth
of M. morganii under the corresponding conditions.
Both trials 1 and 2 were conducted using different starting cultures in order to get accurate
replicates. However, both starting cultures were initially diluted to an OD600 of 0.01 in order
to keep our results consistent. After they were allowed to grow for 8 hours, they were taken
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out of the incubator and their final optical density values were taken with our
spectrophotometer. These values were then plotted on a table and a heat map was constructed
using Microsoft Excel.

Vitamin B12

0
.01 mM
.02 mM
.04 mM
.08 mM
.16 mM
.32 mM
.64 mM
1.28 mM
2.56 mM

Ethanolamine
0 0.01% 0.02% 0.04% 0.08% 0.16% 0.32% 0.64% 1.28%
0.34 0.336
0 0.044
0
0
0
0
0
0.34 0.176 0.012 0.076
0
0
0
0
0
0.332 0.224
0
0
0
0
0
0
0
0.324 0.224 0.016 0.004 0.008 0.004 0.004 0.004 0.004
0.38 0.24 0.028 0.024 0.024 0.0258 0.024 0.024 0.024
0.456 0.256
0.1 0.168 0.072 0.072 0.068 0.076 0.076
0.496 0.376
0.3 0.16 0.152 0.168 0.132 0.144 0.152
0.596 0.504 0.332
0.3 0.312 0.308 0.296 0.328 0.34
0.944 0.808 0.66 0.568 0.652 0.64 0.652 0.604 0.696
1.528 1.592 1.56 1.496 1.32 1.232 1.24 1.232 1.304

Figure 21. Trial 2 for Ethanolamine and Vitamin B12 Experiments. Shown in the figure
are the optical density values for the second trial in our ethanolamine and vitamin B12
experiments. The blue values indicate little to no growth while the red values indicate growth
of M. morganii under the corresponding conditions.
The ethanolamine and vitamin B12 experiments were conducted in order to assess the
relationship between the two carbon sources. The results of our experiments shown in Figure
20 and Figure 21 indicate that not only is M. morganii unable to metabolize ethanolamine
when vitamin B12 is not present, but this carbon source is toxic to it at concentrations higher
than 0.01%. However, as more vitamin B12 is added, the more M. morganii grows.
Therefore, the availability of vitamin B12 affects how well M. morganii is able to metabolize
ethanolamine. In addition, it shows that vitamin B12 can be metabolized on its own as
indicated by its ability to grow even when ethanolamine is absent. This can have larger
implications in the gut where ethanolamine is abundant and mostly utilized by pathogenic
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species of bacteria. How much vitamin B12 is available in the gut can therefore determine
whether M. morganii is competitive with pathogenic species of bacteria. This could further
indicate that utilization of this particular carbon source can be a possible virulence factor
found in M. morganii.
Protein expression profiles
In order to assess differences in protein expression, an SDS-PAGE was conducted on the
carbon sources that did not inhibit growth of M. morganii. Therefore, all of the carbon
sources that were toxic to our bacterium were left out of the protein expression profile due to
the inability of us to be able to grow it in such carbon source, thus being unable to get a
proper sample.
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Figure 22. SDS-PAGE on hexoses. Protein expression profile for M. morganii grown using
hexoses sugars. A is labeled as our protein ladder. B is our control. C is fructose. D is
galactose. E is mannose. F is rhamnose. G is sorbose. H is fucose. I is glucose.
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In Figure 22, the hexose sugars that showed the most prominent differences in protein
expression were found with fructose and mannose. As indicated by both arrows labeled 1,
there is a protein present in the control weighing around 37 kD that is completely absent in
fructose. In addition, as indicated by the arrows labeled 2 there is a protein present in the
control weighing around 25 kD hat is absent in mannose.
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Figure 23. SDS-PAGE on alcohol sugars. Protein expression profile for M. morganii grown
using alcohol sugars. A is our protein ladder. B is our control. C is dulcitol. D is glycerol. E
is inositol. F is mannitol. G is sorbitol. H is xylitol. I is maltitol. J is adonitol.
In Figure 23, the most prominent differences in protein expression were found with dulcitol
and xylitol. As indicated by the arrows labeled 1, the control contains a protein weighing
around 37 kD. However, the M. morganii sample treated with dulcitol does not contain this
band at all indicating the absence of this specific protein. In addition, the sample treated with
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xylitol does contain the band but it is not prominently expressed indicating that less of this
protein was made when compared to the control.
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Figure 24. SDS-PAGE on pentoses, glycosides, sugar acids, fructans, trisaccharides, and
acids. Protein expression profile for M. morganii grown under 6 groups of carbon sources,
pentoses, glycosides, sugar acids, fructans, trisaccharides, and acids. A is our protein ladder.
B is our control. C is arabinose. D is xylose. E is ribose. F is salicin. G is gluconic acid. H is
inulin. I is raffinose. J is citric acid.
In Figure 24, the most prominent differences in protein expression are shown in ribose and
gluconic acid. As indicated by the arrows labeled 1, the control contains a protein weighing
around 25 kD while the M. morganii samples grown with ribose are completely missing this
protein. In addition, as indicated by the arrows labeled 2, the control contains a protein
weighing around 37 kD and while the samples grown with ribose and gluconic acid also
contain this protein, it is only mildly expressed. These results are interesting because these
two carbon sources were shown to provide M. morganii with a growth advantage. However,
there are vast differences in protein expression between the control and these two carbon
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sources because specific proteins are either absent or only mildly expressed. This could
indicate that when M. morganii is not exposed to a particular carbon source it might need to
turn on specific genes in order to synthesize carbon sources in order to survive. That would
explain why when M. morganii is exposed to a particular carbon source, there are certain
proteins that are not expressed.
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Figure 25. SDS-PAGE on amino sugars and disaccharides. Protein expression profile for
M. morganii grown under 2 different groups of carbon sources, amino sugars and
disaccharides. A is our protein ladder. B is our control. C is N-acetylglucosamine. D is
glucosamine. E is cellobiose. F is lactulose. G is sucrose. H is trehalose. I is lactose. J is
maltose.
In Figure 25, the most prominent differences in protein expression are shown in Nacetylglucosamine and glucosamine. As indicated by the arrows labeled 1, the control
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contains a protein that weighs around 37 kD. The samples grown with N-acetylglucosamine

Molecular weight (kD)

and glucosamine also express this protein but only mildly.
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Figure 26. SDS-PAGE on short chain fatty acids, nucleosides, polysaccharides, and
dietary amino acids. Protein expression profile for M. morganii grown under 4 different
groups of carbon sources, short chain fatty acids, nucleosides, polysaccharides, and dietary
amino acids. A is our protein ladder. B is our control. C is acetate. D is propionate. E is
butyrate. F is inosine. G is thymidine. H is dextrin. I is starch. J is ornithine. K is citrulline.
In Figure 26, the most prominent differences in protein expression are shown in acetate and
inosine. As indicated by the arrows labeled 1, there is a protein that weighs around 37 kD
that is seen in our control but it is completely absent in the sample that was grown with
acetate. In addition, as indicated by the arrows labeled 2, there is a protein in our control that
weighs between 25 and 37 kD, but it is completely absent in the samples that were grown in
both acetate and inosine. Inosine was another carbon source that was shown to give M.
morganii a growth advantage. Therefore, the absence of a band could indicate that when M.
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morganii is exposed to inosine, it does not need to make other carbon sources because it is
already using up the carbon source that is present in its environment.
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Figure 27. SDS-PAGE on different carbon sources. Protein expression profiles for M.
morganii grown under different carbon sources. A is our protein ladder. B is our control. C is
urea. D is lactate. E is choline chloride. F is GABA. G is 2-deoxy-D-ribose. H is thiosulfate. I
is casamino acids. J is urea and phosphate.
In Figure 27, the most prominent differences in protein expression are shown in our samples
grown with casamino acids and urea and phosphate. Again, we see a difference in protein
expression in the protein band that weighs around 37 kD indicated by arrow 1. We see that
this band is present in our control but is absent in our sample grown with casamino acids and
only mildly expressed in the sample grown with urea and phosphate. In addition, there is a
protein band present at around 25 kD indicated by arrow 2, that is completely absent in the
samples treated with casamino acids and urea and phosphate. Casamino acids were shown to
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provide a significant growth advantage to M. morganii. Therefore, this follows the pattern
mentioned before that carbon sources that provide M. morganii a growth advantage showed
prominent differences in protein expression. In addition, it also follows the pattern that
protein bands are absent in the samples treated with a particular carbon source when
compared to the control.
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Figure 28. SDS-PAGE on essential amino acids. Protein expression profiles for M.
morganii grown using 12 essential amino acids. A is our protein ladder. B is our control. C is
proline. D is glutamic acid. E is histidine. F is methionine. G is glutamine. H is glycine. I is
lysine. J is serine. K is threonine. L is valine. M is alanine. N is phenylalanine.
In Figure 28, the most prominent differences in protein expression are shown in threonine.
As indicated by the arrows labeled 1, our control contains a protein that weighs around 37
kD. This protein is absent in the sample of M. morganii treated with threonine. In addition,
our control contains two groups of proteins that weigh between 15 and 20 kD. These two
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groups of proteins are also found in the sample grown with threonine, but they are more
overly expressed as indicated by the darker bands.
In all of our protein expression profiles we noticed the most differences between the band
that was found at around 37 kD in our control. In addition, these differences appeared the
most in samples that were treated with a carbon source that was shown to give M. morganii a
growth advantage. This could mean that M. morganii turns on and off certain genes not only
when it is exposed to a particular carbon source in its environment, but when it is exposed to
a carbon source that gives it a growth advantage. These specific proteins can later be studied
when they are sent out for identification via mass spectroscopy.
Metabolic pathways
Metabolic pathways were constructed for the carbon sources that shown to give M.
morganii a growth advantage. They were constructed by using an annotated gene list from
the NCBI database to search for the genes that code for the enzymes found in the metabolic
pathways. KEGG was then used to search for the reference pathways of the metabolites that
were shown to give M. morganii a growth advantage. Once the reference pathways with their
corresponding enzymes were drawn out, the specific enzymes were searched for in the
annotated gene list that was downloaded for M. morganii from the NCBI database. After
drawing out the metabolic pathways for each metabolite, we were surprised to have specific
transporters for almost all of the metabolites. This provided us with a more complete
metabolic pathway for our carbon sources because it shows exactly how these carbon sources
are transported inside of the cell and it shows how they are broken down as well. We were
also able to find that some of the metabolites were transported into the cell via PTS
transporters. As mentioned before, these PTS transporters have been associated with being
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able to turn on specific virulence factors. Therefore, the PTS transporters that we found in M.
morganii for specific metabolites that provided our bacterium with a significant growth
advantage can provide further insight into the association between carbon source metabolism
and virulence.
Xylose
ribose ABC transporter
Xylose
hypothetical protein
D-xylulose
xylulokinase
D-xylulose 5-phosphate
ribulose-phosphate 3epimerase
D-ribulose 5-phosphate
ribose-5-phosphate
isomerase
D-ribose 5-phosphate

Pentose Phosphate
Pathway
Figure 29. Xylose metabolic pathway. Metabolic pathway for the carbon source xylose.
In the metabolic pathway for xylose as shown in Figure 29, the transporter that is used to
transport xylose into the cell is also used to transport the carbon source ribose. Xylose is then
converted to xylulose by a hypothetical protein. This protein was not specifically found in the
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database due to the fact that about 22% of the annotated gene list that we downloaded from
the NCBI database contained hypothetical proteins. However, since M. morganii does
contain the rest of the enzymes needed to metabolize xylose, we are fair to assume that it
does contain the enzyme needed to convert xylose to xylulose.
Xylitol
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reductase

D-xylulose 5-phosphate
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D-ribulose 5-phosphate

Ribulose
phosphate 3epimerase

Pentose Phosphate Pathway

Figure 30. Xylitol metabolic pathway. Metabolic pathway for the carbon source xylitol.
In the metabolic pathway for xylitol as shown in Figure 30, a putative xylitol transport
protein first transports xylitol into the cell. Afterwards, a series of reactions convert it to Dribulose-5-phosphate which can then enter the pentose phosphate pathway.
D-gluconate

D-gluconate
Low-affinity
gluconate/
𝑯"
symporter

6-phospho-D-gluconate

Gluconokinase

Phosphogluconate
dehydratase

6-phosphogluconate
dehydrogenase
D-ribulose 5phosphate
Ribose 5phosphate
isomerase A
D-ribose 5- Ribokinase
phosphate

2-dehydro-3-deoxy-6-phospho-D-gluconate
2-dehydro-3deoxyphosphogluconate
aldolase
Pyruvate
+
D-glyceraldehyde
3-phosphate

D-ribose

Ribose-phosphate
pyrophosphokinase
Glycolysis
5-phospho-alpha-D-ribose-1-diphosphate
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Figure 31. Gluconic acid (Gluconate) pathway. Metabolic pathway for the carbon source
gluconic acid.
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In the metabolic pathway for gluconic acid or gluconate as shown in Figure 31, gluconate is
first transported into the cell via a low-affinity gluconate/H+ symporter. Once inside the cell,
the pathway takes many directions. Gluconate can eventually be converted to PRPP which
can be used for purine, pyrimidine, and histidine biosynthesis, or it can eventually be
converted to pyruvate and D-glyceraldehyde 3-phosphate which can then enter the citric acid
cycle and glycolysis respectively.
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Figure 32. Galactose pathway. Metabolic pathway for the carbon source galactose.
In the metabolic pathway for galactose as shown in Figure 32, galactose is transported into
the cell via a galactose/glucose ABC transporter. Galactose then eventually gets metabolized
into D-glucose 1-phosphate which can enter glycolysis and into UDP-glucose which can
enter the metabolic pathways for ascorbate and aldarate as well as those for amino sugars and
nucleotide sugars. Galactose is transported into the cell via an ABC transporter as opposed to
a PTS transporter. Therefore, this could indicate that galactose is not able to turn on specific
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virulence factors. This would make sense because galactose is a fairly common sugar in the
human gut and M. morganii is known to be a commensal species of bacteria.

Mannose

D-mannose 6-phosphate
PTS system
mannose
specific IIA
and IIB

D-fructose 6-phosphate
Mannose 6-phosphate isomerase

Glycolysis

Phosphoglucomutase

D-mannose 1-phosphate

Figure 33. Mannose pathway. Metabolic pathway for the carbon source mannose.
In the metabolic pathway for mannose as shown in Figure 33, mannose is first transported
into the cell via a PTS system that is specific to mannose. This system simultaneously
transports and phosphorylates mannose as it enters the cell. The main course of action for
mannose is then to be converted to D-fructose 6-phosphate which is a product that can enter
glycolysis. Mannose is a fairy common monosaccharide sugar that is abundant in the human
gastrointestinal tract. The fact that mannose is transported into the cell via a PTS transporter
could indicate that mannose has the ability to turn on specific virulence factors. With
mannose being a common sugar, it could also indicate that M. morganii has the ability to
switch from a saprophytic to a pathogenic lifestyle rather easily. However, it could also
indicate that mannose is not able to turn on specific virulence factors since M. morganii is
constantly being exposed to this carbon source in the human gut environment. It is possible
that these PTS transporters are able to turn on specific virulence factors only when they are
exposed to more exotic sugars that are less common in the human gut environment. The
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presence of these sugars could signal to M. morganii that it would need to become
pathogenic in order to use alternative carbon sources in order to outcompete other species of
bacteria.
N-acetyl-D-glucosamine
PTS system, Nacetylglucosamine-specific
IIABC component protein
N-acetyl-D-glucosamine 6-phosphate
N-acetylglucosamine 6phosphate deacetylase
D-glucosamine 6-phosphate
glucosamine 6-phosphate
deaminase
D-fructose 6-phosphate

Glycolysis

Figure 34. N-acetyl-D-glucosamine pathway. Metabolic pathway for the carbon source Nacetyl-D-glucosamine.
In the metabolic pathway for N-acetyl-D-glucosamine as shown in Figure 34, this metabolite
is first transported and simultaneously phosphorylated by a PTS system specific for N-acetylD-glucosamine. It eventually gets metabolized to D-fructose 6-phosphate which then enters
glycolysis. N-acetyl-D-glucosamine is transported into the cell via a PTS transporter. This
could indicate that N-acetyl-D-glucosamine has the potential to turn on specific virulence
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factors. However, unlike mannose N-acetyl-D-glucsoamine is a more exotic sugar so it
would make more sense for it to be able to turn on specific virulence factors.
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Figure 35. Glycerol pathway. Metabolic pathway for the carbon source glycerol.
In the metabolic pathway for glycerol as shown in Figure 35, this metabolite is first
transported into the cell via a glycerol uptake facilitator protein. It then undergoes a series of
reactions that converts it to D-glyceraldehyde 3-phosphate which can then enter the
glycolytic pathway. Glycerol is transported into the cell via an uptake facilitator protein as
opposed to a PTS system. Therefore, it is highly unlikely that glycerol is able to turn on
specific virulence factors. However, M. morganii’s ability to transport and metabolize
glycerol could have larger implications in terming M. morganii a weight protective species of
bacteria. Glycerol is a component of fatty acids. Therefore, if M. morganii is able to utilize
glycerol it could also mean that it is able to break apart these fatty acids. If it is able to break
apart these fatty acids and eventually metabolize one of its parts to D-glyceraldehyde-3phosphate, then it would be able to utilize these fatty acids to make more energy via the
glycolytic pathway. This would give M. morganii an advantage over other species of bacteria
because it would be able to utilize an alternative carbon source.
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Figure 36. Glycolytic pathway. Metabolic pathway for the carbon source glucose.
The metabolic pathway for glucose as shown in Figure 36, is universally found in all living
organisms that use glucose to make energy. In M. morganii it is no different. In the glycolytic
pathway glucose eventually gets converted into pyruvate which can then enter the citric acid
cycle which can then help power the electron transport chain that produces large amounts of
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energy. Most of the energy that bacteria utilize come from this pathway. For this reason,
most of the end products from the pathways constructed in this study empty out into the
glycolytic pathway.
Fructose
PTS mannose/fructose/sorbose
transporter
D-fructose 6-phosphate

Glycolysis

Figure 37. Fructose pathway. Metabolic pathway for the carbon source fructose.
In the fructose pathway as shown in Figure 37, fructose is simultaneously transported and
phosphorylated by a PTS system specific for mannose, fructose, and sorbose. This
phosphorylated product is then able to enter the glycolytic pathway in the form of D-fructose
6-phosphate. In this case, fructose is transported into the cell via a PTS transporter. However,
immediately after it is transported into the cell, it enters the glycolytic pathway. Therefore, it
is possible that fructose is not used to turn on specific virulence factors via the PTS
transporter. In addition, fructose is a very common sugar that is abundant in the human gut.
Therefore, much like mannose, it would not make much sense if this carbon source is able to
switch M. morganii from a saprophytic into a pathogenic lifestyle.
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Figure 38. Ribose pathway. Metabolic pathway for the carbon source ribose.
In the metabolic pathway for ribose as shown in Figure 38, ribose first gets transported into
the cell via an ABC transporter. It then gets metabolized into PRPP which can then enter the
metabolic pathways for purines, pyrimidines, and histidine. Since PRPP is used to make
purines and pyrimidines, this could mean that ribose provides a growth advantage for M.
morganii by providing the nucleotides necessary to assist in DNA synthesis. In addition, it
also showed the ability to undergo histidine metabolism. Histidine is an amino acid that was
shown to give M. morganii a growth advantage. Therefore, this could possibly mean that
ribose is needed in order for histidine to be metabolized by M. morganii.
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Figure 39. D-glucosamine pathway. Metabolic pathway for the carbon source Dglucosamine.
In the metabolic pathway for D-glucosamine as shown in Figure 39, D-glucosamine is
simultaneously transported and phosphorylated via a PTS sugar transporter. It then gets
metabolized into D-fructose 6-phosphate which can then enter glycolysis. The metabolic
pathway for D-glucosamine is very similar to the pathway for N-acetyl-D-glucosamine due
to their similar structures. They undergo similar reactions that both have the same end
product, D-fructose 6-phosphate. In addition, D-glucosamine is transported into the cell via a
PTS transporter. It is fair to assume that this PTS transporter is the same one that transports
N-acetyl-D-glucosamine into the cell. Therefore, it is possible that D-glucosamine could also
have the ability to turn on specific virulence factors since it is also considered a more exotic
sugar.
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Figure 40. Starch pathway. Metabolic pathway for the carbon source starch.
In the metabolic pathway for starch as shown in Figure 40, we were unable to find the both
the transporter protein and the protein that it utilized to break apart starch into D-glucose 1phosphate. However, once D-glucose 1-phosphate is present, M. morganii contains an
enzyme named phoshoglucomutase that converts this metabolite into D-glucose 6-phosphate
which can then enter glycolysis. In addition, it is possible that starch is broken down in the
human gastrointestinal tract before it is uptaken by M. morganii. M. morganii is able to
utilize glucose and it is able to transport it into the cell. The polysaccharide starch is
composed of a long chain of these glucose units. Therefore, it would make sense that it is
able to both transport and metabolize these glucose units. These glucose units would enter
the glycolytic pathway and eventually be used as energy to power the cell.
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Figure 41. Thymidine pathway. Metabolic pathway for the carbon source thymidine.
In the thymidine pathway as shown in Figure 41, we were unable to find a transporter
protein. However, thymidine is metabolized into nucleotides that can then be utilized for the
synthesis of DNA. Being that DNA synthesis is crucial during cellular replication, DNA
synthesis eventually allows a bacterium to grow by allowing it to replicate and pass on its
genetic machinery to other cells. Therefore, this is an example of a carbon source that has an
indirect effect on the growth of M. morganii, but nonetheless helps our bacterium exhibit
growth.
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Figure 42. Inosine pathway. Metabolic pathway for the carbon source inosine.
In the inosine pathway as shown in Figure 42, we were unable to find a transporter protein.
However, we found that the metabolic pathway for inosine takes two directions. Inosine can
be metabolized to D-ribose which can then enter the pentose phosphate pathway or it can be
metabolized into a nucleotide which can then be used for the synthesis of DNA.
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Figure 43. Serine pathway. Metabolic pathway for the amino acid serine.
In the metabolic pathway for serine as shown in Figure 43, serine is first transported into the
cell via a serine transporter. Serine can then be metabolized into another amino acid named
cysteine which can then be used for sulfur metabolism or it can be metabolized into pyruvate
which is then able to enter the citric acid cycle. The ability of serine to be converted into
another amino acid is of great importance in this case because cysteine is an amino acid that
did not provide M. morganii with a significant growth advantage. Therefore, this could
indicate that M. morganii compensates for its inability to utilize a specific carbon source by
converting another carbon source into the missing metabolite. This would allow M. morganii
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to require less genetic machinery to metabolize more carbon sources. Therefore, this would
allow M. morganii to expend less energy to do so.
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Figure 44. Histidine pathway. Metabolic pathway for the amino acid histidine.
As seen in Figure 44, the metabolic pathway for histidine in M. morganii is mostly
hypothetical. We were only able to find one protein that is able to convert histidine into
histamine. However, according to our reference pathways it is possible to convert histidine
into the two amino acids aspartate and glutamate. These two amino acids were not shown to
provide M. morganii a growth advantage. Therefore, this could also mean that M. morganii is
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trying to compensate for the carbon sources that it cannot utilize by converting a metabolite
into a usable carbon source.
Proline
proline/glycine ABC transporter
Proline
pyrroline-5-carboxylate
reductase
L-pyrroline-5-carboxylate
L-glutamate gammasemialdehyde dehydrogenase

proline dehydrogenase

L-glutamate 5-semialdehyde

Amino acid synthesis
(glutamate)

Figure 45. Proline pathway. Metabolic pathway for the amino acid proline.
As seen in Figure 45, in the metabolic pathway for proline, proline is first transported into
the cell via a proline/glycine transporter. It is then metabolized into L-glutamate 5semialdehyde which can then be used to synthesize the amino acid glutamate. It is worth
noting that glutamate is an amino acid that does not give M. morganii a growth advantage
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nor did we find it to be toxic. Therefore, it is possible that M. morganii does not need to
uptake this specific amino acid because it is able to synthesize it when it needs it.

Threonine
serine/threonine transporter
Threonine
threonine ammonia-lyase
2-oxobutanoate

Valine, leucine, and
isoleucine biosynthesis

Figure 46. Threonine pathway. Metabolic pathway for the amino acid threonine.
In the metabolic pathway for threonine as shown in Figure 46, threonine is first transported
into the cell via a serine/threonine transporter. Threonine is then metabolized into 2oxobutanoate which can then be used in the biosynthesis of the amino acids valine, leucine,
and isoleucine. It is worth noting that these amino acids were also tested for in our growth
experiments and it was found that they did not provide M. morganii with a growth advantage.
The reason being could be that they are already being synthesized inside the cell so there is
no need for M. morganii to utilize these exogenous carbon sources. This follows the pattern
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seen when M. morganii was able to convert serine into cysteine and when it was able to
convert histidine into aspartate and glutamate.

Methionine
methionine ABC transporter
Methionine
methionine gamma-lyase

Methanethiol

Sulfur metabolism

Figure 47. Methionine pathway. Metabolic pathway for the amino acid methionine.
In the metabolic pathway for methionine as shown in Figure 47, methionine is first
transported into the cell via an ABC transporter. It is then eventually metabolized into
methanethiol which can further be used for sulfur metabolism. Methionine is one of only two
amino acids that contains sulfur, so both of these amino acids are utilized by M. morganii in
sulfur metabolism. This is another example of a carbon source that has an indirect effect on
the growth of M. morganii, but nonetheless helps it grow. Most of the other carbon sources
empty out into the glycolytic pathway, so they allow M. morganii to grow by providing it
with the energy it needs in order to surivive.

69

L-glutamine
glutaminase

L-glutamate
glutamate racemase

D-glutamate
UDP-N-acetylmuramoyl-Lalanine—D-glutamate ligase
UDP-N-acetylmuramoyl-L-alanyl-D-glutamate

Peptidoglycan biosynthesis

Figure 48. Glutamine pathway. Metabolic pathway for the amino acid glutamine.
In the metabolic pathway for glutamine as shown in Figure 48, we were unable to find a
specific transporter for this amino acid. However, M. morganii contains several non-specifc
amino acid transporters that could have possibly been used to uptake glutamine. In addition,
it shows that in M. morganii glutamine is mainly used to help form peptidoglycan which is
part of the cell wall for our bacterium. Therefore, this carbon source provides structural
support for our cell. This can allow our bacterium to have a higher survival rate and as a
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result, it can allow it to replicate more. This would account for the growth advantage that we
noticed when M. morganii was exposed to glutamine.
Disk diffusion assays
Disk diffusion assays were conducted on M. morganii in order to determine which
antibiotics our bacterium was resistant to. A list of the antibiotics as well as their respective
zones of inhibition and interpretative MIC values are shown in Table 4.
Table 4. Disk diffusion assay results.

Class
Aminoglycoside
Aminoglycoside
Amphenicol
Beta-Lactam
Carbapenem
Cephalosporin
Cephalosporin
Fluoroquinolone
Fluoroquinolone
Macrolide
Nitrofuran
Tetracycline
Tetracycline

Antibiotic
Gentamycin
Kanamycin
Chlromphenicol
Ampicillin
Imipenem
Cefazolin
Ceftriaxone
Ciprofloxacin
Levofloxacin
Azithromycin
Nitrofurantoin
Tetracycline
Doxycycline

Zone of
inhibition
(mm):
Trial 1
8
5
4
9
0
0
11
0
0
3
0
4
4

Zone of
inhibition
(mm):
Trial 2
9
5
4
10
0
0
10
0
0
3
0
4
5

Interpretive
MIC
≥16
≥64
≥32
≥32
≥4
≥32
≥16
≥4
≥8
≥32
≥128
≥16
≥16

Interpretive
Category
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant
Resistant

M. morganii was tested against several classes of antibiotics. Two trials were conducted and
the zones of inhibition were noted. The zones of inhibition were then used to find the
interpretative MIC as well as the interpretative category to determine whether M. morganii
was susceptible or resistant to the antibiotic being tested. It was found that M. morganii was
resistant to all of the antibiotics tested according to the manual created by the CLSI.
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DISCUSSION
Morganella morganii is a member of the human gut microbiota that is known to
cause a wide array of infections, including nosocomial infections due to its opportunistic
nature. It is an organism that despite having its full genome sequenced, it has not been
extensively studied. Therefore, this study focused on creating a basic metabolic and drug
resistance profiles for this organism. This study was able to determine which metabolites
were utilized by M. morganii and which ones proved to be harmful to our organism. We were
able to find 23 metabolites that provided M. morganii with a growth advantage and 12 that
were shown to be toxic to our organism. Amongst those that gave M. morganii a growth
advantage, there were two carbon sources that were initially not being metabolized by M.
mroganii despite containing the necessary genetic machinery to do so. These two carbon
sources were urea and ethanolamine. After searching the literature, it was discovered that
these two carbon sources needed to be supplemented with phosphate and vitamin B12,
respectively [45, 46]. Our experiments confirmed this and also provided insight into exactly
how much of these supplements need to be added to our initial carbon source in order for
significant growth to occur. Urea is a prominent carbon and nitrogen source that is mostly
utilized by pathogenic species of bacteria that are known to cause UTIs [39]. Morganella
morganii contains the urease gene cluster ureABCEFGD and the urea transporter that allows
it to metabolize urea [28]. Therefore, M. morganii’s ability to utilize this metabolite can
affect its ability to become pathogenic. Additionally, M. morganii contains an eut operon that
allows it to metabolize ethanolamine [27]. Ethanolamine is a component of
phosphatidylethanolamine (PE) which is the second most abundant phospholipid in
mammalian cells [50]. Ethanolamine is available when it is attached to PE in the cell
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membrane and it is also present as free ethanolamine in body fluids [50]. Since pathogenic
species of bacteria are able to cause infection by penetrating the epithelial layer, M.
morganii’s ability to utilize ethanolamine can contribute to its ability to become pathogenic.
It can also mean that vitamin B12 can act as a switch for M. morganii to become pathogenic
because if enough vitamin B12 is present in its environment it is able to utilize ethanolamine
and thereby penetrate the epithelial layer to consume this metabolite. In addition, utilization
of ethanolamine by M. morganii can give our bacterium a competitive advantage over other
species of bacteria since it is able to utilize a metabolite not commonly used by commensal
bacteria. These experiments provide a basis for future adaptation experiments because it
allowed us to determine which metabolites M. morganii utilizes at the moment. Additionally,
once we determined which metabolites gave M. morganii a growth advantage, we were able
to create metabolic pathways that traced how these metabolites were broken down by our
organism using an annotated gene list that was downloaded from the NCBI database.
Interestingly, we were able to find transporter proteins for most of the metabolites that
provided M. morganii with a growth advantage thus indicating that it is readily able to take
up these exogenous carbon sources. In some cases, we were even able to find that the carbon
sources that M. morganii would metabolize would end up synthesizing other metabolites that
it did not necessarily utilize when it was present in its environment. This ended up being true
for the threonine, proline, and histidine pathways. These pathways give us a basic overview
at what is happening inside of the bacterial cell once the given carbon source is taken up.
With species belonging to the human gut microbiota this becomes important to know because
in the gastrointestinal tract, there are a variety of species of bacteria that are competing for
nutrients. In order for a bacterium to survive, it must have the necessary machinery to break
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down the metabolites that it is being exposed to in its environment. In addition, we were able
to produce a basic protein expression profile using SDS-PAGE. This provided insight into
how M. morganii alters its gene expression based on the metabolite that it is being exposed
to. We noticed the most differences with a protein group present in the control that weighs
around 37 kD. This band was very prominent in the control but its level of expression would
differ when compared to samples that were actually treated with a particular carbon source.
This was the case with the bacterial samples treated with fructose, xylitol, dulcitol, gluconic
acid, ribose, glucosamine, N-acetylglucosamine, acetate, and threonine. This can further help
us understand how M. morganii is able to adapt to its environment. Since it is a member of
the gut microbiota that is known to be an opportunistic pathogen, these kinds of studies
become important in order to gain insight as to how it is able to alternate between a
saprophytic to a pathogenic lifestyle. Lastly, we were able to test which antibiotics M.
morganii was resistant to. In our tests, M. morganii ended up being resistant to all of the
antibiotics tested. Nine major classes of antibiotics were tested for including the class named
carbapenem which includes the antibiotic imipenem. Antibiotics belonging to the
carbapenem class have been named the antibiotics of last resort due to the fact that they are
often the only antibiotics that are effective at treating bacterial infections [48]. In our tests,
when M. morganii was treated with imipenem there was no visible zone of inhibition. This
means that our bacterium contains the necessary resistance mechanisms to make it
completely resistant to this drug of last resort. This is of critical importance due to the fact
that in the human gut M. morganii is in constant interaction with not only its environment but
also with other bacteria. When bacteria are in close interactions with each other, the process
of horizontal transfer can occur [49]. This can allow M. morganii to exchange its genetic
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information with other species of bacteria, thereby promoting these resistance mechanisms.
Therefore, this raises concern as to if we will be able to combat these types of infections
when they are encountered.
The experiments that we conducted were able to create a basic metabolic and drug
resistance profile for M. morganii. In the future, this metabolic and drug resistance profile
can be extended to include more metabolites and more antibiotics. This will allow us to
further understand how M. morganii is able to interact with its environment. In addition,
future studies could focus on adaptation mechanisms utilized by M. morganii in order to
adapt to the highly dynamic human environment. This can be accomplished by repeating our
growth experiments with a more recently isolated sample of M. morganii in order to
determine if it has gained the ability to metabolize carbon sources that it was previously
unable to use. In addition, adaptation experiments can also be conducted by forcing our
organism to adapt to otherwise toxic metabolites by slowly increasing the concentration of
such carbon sources.
The human gut is a highly dynamic environment that contains many species of
bacteria in constant interaction with each other and with their environment. There are too
many interactions going on to be able to study all of them at one time. Therefore, it is
important to study individual interactions from each bacterial species first in order to
understand one piece of the puzzle at a time. Our study was able to accomplish this.
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